Cardiomyocyte Alpha-1A Adrenergic Receptors Mitigate Postinfarct Remodeling and Mortality by Constraining Necroptosis

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Molecular Biology

Background:

• Alpha1-adrenergic receptor antagonists (alpha-blockers) are linked to increased heart failure risk.
• The precise mechanism, whether direct cardiomyocyte effects or systemic influences, remains unclear.

Purpose of the Study:

• To investigate the role of cardiomyocyte alpha1-ARs in heart failure risk associated with alpha-blocker use.
• To elucidate the underlying mechanisms contributing to adverse cardiovascular events.

Main Methods:

• Generated a mouse model with cardiomyocyte-specific deletion of the alpha1A-AR subtype.
• Assessed mortality and necroptosis activation following myocardial infarction in the mouse model.
• Correlated animal model findings with clinical data from patients using alpha-blockers.

Main Results:

• Mice with cardiomyocyte alpha1A-AR deletion exhibited 70% mortality within 7 days of myocardial infarction.
• Increased necroptosis activation was a key factor in the observed mortality.
• Clinical data confirmed an elevated risk of death post-myocardial infarction in patients taking alpha-blockers.

Conclusions:

• Cardiomyocyte alpha1A-ARs play a critical role in mediating the adverse effects of alpha-blockers on heart function post-myocardial infarction.
• Excessive necroptosis contributes to increased mortality in this context.
• Findings support a direct role of cardiomyocyte alpha1-AR signaling in cardiovascular risk.